Sekisui Spectrolyse PAI-1, In-Vitro Diagnostic for Quantitative determination of Plasminogen Activator Inhibitor Type- 1 (PAI-1) activity in human plasma. Catalog Number: 101201 For the determination of Plasminogen Activator Inhibitor Type 1 (PAI-1) activity in human plasma. The test is for in Citro diagnostic use.
Published September 26, 2012 · Recall initiated: August 28, 2012
Summary
FDA records medical device Class II recall Z-2431-2012, published September 26, 2012 and initiated August 28, 2012. Recalling firm: Sekisui Diagnostics Llc; Status: Terminated; Reported quantity: 699 kits; Lot: Lot Numbers: 120425 and 120601. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
SPECTROLYSE PAI-1 activity assay producing lower than expected absorbance values with "0" standard. This will reduce the slope of the standard curve requiring the user to make more frequent sample dilutions.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Sekisui Diagnostics Llc
- Distributor
- Nationwide distribution: USA including states of: FL, IN, IL, and WA.
- Lot
- Lot Numbers: 120425 and 120601
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDASekisui Diagnostics, Spectrolyse PAI-1 In-Vitro Diagnostic Use for the quantitative determination ofDecember 12, 2012
- FDACARDIOGEN-82 (Rubidium Rb 82 Generator), 140 millicurie, Rx Only, For Elution of sterile nonpyrogenic RubidiumOctober 3, 2012
- FDAPropofol Injectable Emulsion, 1%, packaged in a) 20 mL Single patient infusion vial, 200 mg/20 mL (10 mg/mL),October 3, 2012
- FDAModel 324JL On-Board Suction System Intended use: On-board suction system for Ambulance manufacturers.September 26, 2012
- FDAIntegra HRAIM Head Ring Assembly with Intubation Mounts The CRW stereotactic system is used in conjunctionSeptember 26, 2012
- FDAMULTIGENT Acetaminophen for use with Architect/Aeroset Cat. No. 2K99-20. Assay is intended for theJuly 4, 2012
Questions about this recall
Was Sekisui Spectrolyse PAI-1, In-Vitro Diagnostic for Quantitative determination of Plasminogen Activator Inhibitor Type- 1 (PAI-1) activity in human plasma. Catalog Number: 101201 For the determination of Plasminogen Activator Inhibitor Type 1 (PAI-1) activity in human plasma. The test is for in Citro diagnostic use. recalled?
Yes. FDA published recall Z-2431-2012 on September 26, 2012. Reported hazard: SPECTROLYSE PAI-1 activity assay producing lower than expected absorbance values with "0" standard. This will reduce the slope of the standard curve requiring the user to make more frequent sample dilutions.
What should I do if I have this product?
Voluntary: Firm initiated · Letter